January 7, 2021 -- MilliporeSigma has purchased messenger RNA (mRNA) firm AmpTec. The deal is expected to boost MilliporeSigma's ability to develop and manufacture mRNA for use in COVID-19 vaccines and treatments.
AmpTec's polymerase chain reaction (PCR)-based technology has benefits over other technologies for mRNA manufacturing, including better homogeneity, purity, and activity and improved performance, according to MilliporeSigma. As well, AmpTec's diagnostics business, which produces customized long RNAs and DNAs for in vitro diagnostics, will complement MilliporeSigma's own diagnostics business, it said.